Indicated for: nasal congestion; rhinitis
Route of administration: nasal
Substance: xylometazoline + ipratropium (adrenergic decongestant + antimuscarinic bronchodilator)
ATC: R01AB06 (Respiratory system | Decongestants and other nasal preparations for topical use | Sympathomimetics, combinations excl. corticosteroids)
This medicine may cause dizziness or vertigo.
Use caution if you have glaucoma or increased eye pressure.
May cause dry mouth, constipation, urinary retention, or blurred vision.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Older people may have an increased risk of side effects.
This medicine may increase the risk of heart rhythm disturbances.
The combination of xylometazoline and ipratropium is used for the symptomatic treatment of nasal congestion and rhinorrhea associated with the common cold or allergic rhinitis. Xylometazoline is a nasal decongestant that works by constricting blood vessels in the nasal mucosa, thereby reducing swelling and congestion. Ipratropium is an anticholinergic that reduces nasal secretions by inhibiting the activity of serous and mucous glands.
This combination is administered as a nasal spray, usually 2-3 times a day, depending on the severity of symptoms. It is intended for short-term use, typically no more than 7 days, to avoid the risk of rebound rhinitis.
Common side effects include nasal dryness, mucosal irritation, a burning sensation, and, in rare cases, nosebleeds. Systemic reactions such as headaches or dizziness may also occur, especially if the medication is overused.
Patients using this combination should adhere to the recommended dosage and avoid prolonged use. The combination of xylometazoline and ipratropium provides an effective solution for rapid relief of nasal symptoms, improving patient comfort during episodes of severe nasal congestion.